Posttransplant diabetes mellitus (PTDM) is awell-recognized complication of heart transplantation and is associated with increased\nmorbidity and mortality. Previous studies have yielded wide ranging estimates in the incidence of PTDM due in part to variable\ndefinitions applied. In addition, there is a limited published data on the management of PTDM after heart transplantation and\na paucity of studies examining the effects of newer classes of hypoglycaemic drug therapies. In this review, we discuss the role\nof established glucose-lowering therapies and the rationale and emerging clinical evidence that supports the role of incretinbased\ntherapies (glucagon like peptide- (GLP-) 1 agonists and dipeptidyl peptidase- (DPP-) 4 inhibitors) and sodium-glucose\ncotransporter 2 (SGLT2) inhibitors in the management of PTDM after heart transplantation. Recently published Consensus\nGuidelines for the diagnosis of PTDM will hopefully lead to more consistent approaches to the diagnosis of PTDM and provide a\nplatformfor the larger-scalemulticentre trials that will be needed to determine the role of these newer therapies in themanagement\nof PTDM.
Loading....